MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults and children. Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy. The presence of hAFP in the pregnant mother’s blood has long been associated with remission of many autoimmune diseases, including rheumatoid arthritis, psoriasis and multiple sclerosis, during the third trimester of pregnancy. Current studies are assessing MM-093’s potential to improve the treatment of autoimmune disease.
Investigated for use/treatment in autoimmune diseases, psoriasis and psoriatic disorders, and rheumatoid arthritis.
East Valley Rheumatology & Osteoporosis, Gilbert, Arizona, United States
Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States
Montgomery Rheumatology Associates, Montgomery, Alabama, United States
MERSI, Cambridge, Massachusetts, United States
U. of Utah School of Medicine- Department of Dermatology, Salt Lake City, Utah, United States
Texas Dermatology Research Institute, Dallas, Texas, United States
New England Research Associates, Bridgeport, Connecticut, United States
Rheumatology Associates, PC, Indianapolis, Indiana, United States
Houston Institute for Clinical Research, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.